CN102697894A - Medicinal composition for treating nasal cavity inflammatory disease and preparation method thereof - Google Patents
Medicinal composition for treating nasal cavity inflammatory disease and preparation method thereof Download PDFInfo
- Publication number
- CN102697894A CN102697894A CN2012101801722A CN201210180172A CN102697894A CN 102697894 A CN102697894 A CN 102697894A CN 2012101801722 A CN2012101801722 A CN 2012101801722A CN 201210180172 A CN201210180172 A CN 201210180172A CN 102697894 A CN102697894 A CN 102697894A
- Authority
- CN
- China
- Prior art keywords
- parts
- nasal cavity
- rhinitis
- medicinal composition
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a medicinal composition for treating a nasal cavity inflammatory disease. The medicinal composition is called 'anti-rhinitis medicament'. The medicinal composition comprises the following raw materials in parts by weight: 5-15 parts of magnolia flower, 8-20 parts of dahurian angelica root, 10-30 parts of Japanese raspberry herb and 5-15 parts of leucas chinensis. As proved by clinical test, the medicinal composition for treating the nasal cavity inflammatory disease disclosed by the invention has the effects of expelling wind, clearing away cold, dredging channels, smoothening air flow, reduce swelling, alleviating pain, and repairing nasal cavity mucosa pathological tissues. The medicinal composition disclosed by the invention is suitable for rhinitis such as chronic rhinitis, nasosinusitis and allergic rhinitis. The medicinal composition has the advantages of simple composition, preparation from pure Chinese medicinal components, reasonable composition, freeness from side effect, convenience for using, capability of curing in one treatment course, good and stable curative effect and low recurrence rate, and can be used for curing various nasal cavity diseases such as rhinitis, nasosinusitis and the like.
Description
Technical field
The invention belongs to the field of Chinese medicines, relate to a kind of pharmaceutical composition that is used to treat nasal cavity inflammation property disease.
Background technology
Nasal cavity inflammation property disease is meant the inflammation of the nasal membrane that virus, antibacterial, allergen, various physical and chemical factor and some systemic disease cause; Main pathological change is mucous hyperemia, swelling, ooze out, hypertrophy, atrophy or necrosis etc., causes various nasal cavity symptoms.Common nasal cavity inflammation property disease comprises: acute or chronic rhinitis; Acute and chronic sinusitis; Allergic rhinitis; Vasomotor rhinitis; The atrophic rhinitis.Nasal cavity inflammation property disease is endangering the healthy of people as a kind of common disease, brings a lot of inconvenience to the people, and especially chronic rhinitis, sinusitis etc. are difficult to the stubborn disease of curing especially.
Chinese medicine takes stopgap measures and effects a permanent cure, and has no side effect, and rather people accept and select for use, and Chinese medicine has been widely used in treating multiple disease, and is respond well.People also attempt adopting the treatment by Chinese herbs rhinitis.At present, the considerable patent application that relates to the Chinese medicine preparation of treating rhinitis is arranged.For example; Application for a patent for invention " a kind of Chinese patent medicine of treating the rhinitis " (application number 96114396.7 that tiger is luminous; 1996 applyings date December 18 days; Open day on November 25th, 1998) disclosing a kind of rhinitis of treating is main Chinese patent medicine preparation, contains Fructus Xanthii, Herba Asari, the Radix Angelicae Dahuricae, Radix Notoginseng, Borneolum Syntheticum, Semen Juglandis wet goods Six-element Chinese medicine ingredients in the said preparation, processes the medicine oil spray nose of external.This patent application in bulletin deemed withdrawal on November 25th, 1998, confirms its curative effect without practice.Again for example; The application for a patent for invention of Liu Chaobing " a kind of Chinese medicine of treating acute and chronic rhinitis, sinusitis " (application number 00102023.4; January 30 2000 applying date; Open day August 8 calendar year 2001) a kind of Chinese medicine of treating acute and chronic rhinitis, sinusitis is disclosed; Be the medicament of being processed by the following weight proportion raw material, Fructus Xanthii 8-20, Flos Magnoliae 8-20, windproof 5-12, the Radix Angelicae Dahuricae 8-20, Flos Lonicerae 10-20, Folium Perillae 8-15, Cicadae move back 5-15, Herba Schizonepetae 5-15, Herba Asari 1-8, Rhizoma Chuanxiong 5-15, Radix Glycyrrhizae 2-15.This patent application is authorized, and belongs to hospital the applicant and carry out application.Can find that through analyzing these disclosed Chinese medicine preparation that are used to treat rhinitis all need Six-element or more raw material of Chinese medicine to process, and composition and component differ greatly, each is variant for performance, effect.Therefore, need a kind of composition of exploitation simpler clear and definite, preparation easily can keep the Chinese medicine preparation of higher curative effect again.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition that is used to treat nasal cavity inflammation property disease; This pharmaceutical composition adopts the brand-new prescription based on Chinese crude drug; Only need four flavor Chinese medicines, and have that good effect, efficacy stability, relapse rate are low, preparation and characteristics such as easy to use.
A kind of pharmaceutical composition that is used to treat nasal cavity inflammation property disease of the present invention, each raw materials in part by weight is: Flos Magnoliae 5-15 part, Radix Angelicae Dahuricae 8-20 part, Rubus Parvifolius L. 10-30 part, Pemisetum flaccidum Griseb 5-15 part.
Preferably, in the pharmaceutical composition of the present invention, each raw materials in part by weight is: 10 parts of Flos Magnoliaes, 12 parts of the Radixs Angelicae Dahuricae, 20 parts of Rubus Parvifolius L.s, 10 parts of Pemisetum flaccidum Grisebs.
Flos Magnoliae: suffering, temperature attaches to the lung and stomach meridians, and it is cold to dispel the wind, and clearing the nasal passage is used for headche due to wind-cold, nasal obstruction, nasal sinusitis, turbid nasal discharge.The Radix Angelicae Dahuricae: suffering, temperature attaches to the lung and stomach meridians, expelling wind and cold, understand things pain-stopping, detumescence and apocenosis, dampness leukorrhagia stopping.Rubus Parvifolius L.: sweet, sour, cool, return liver, stomach, lung, urinary bladder channel, dissipating blood stasis, pain relieving, detoxifcation, parasite killing.Be used for haematemesis, traumatic injury knife injury, the stagnant stomachache of the stasis of blood in puerperal, dysentery, hemorrhoid, scabies.Clearing away heat and cooling blood, eliminating stagnation, pain relieving, inducing diuresis to remove edema.Pemisetum flaccidum Griseb: sweet in the mouth; Little hardship; Property is put down, clearing away heat-damp and promoting diuresis.
Pharmaceutical composition of the present invention can be used for treating following nasal cavity inflammation property disease: chronic rhinitis; Sinusitis; Allergic rhinitis; Vasomotor rhinitis; The atrophic rhinitis.
According to pharmaceutical composition of the present invention, can be made into the outer dosage form that is coated with use, for example unguentum.
The present invention also provides a kind of described preparation of drug combination method that is used to treat nasal cavity inflammation property disease.
This method for preparing may further comprise the steps: take by weighing Flos Magnoliae, the Radix Angelicae Dahuricae, Rubus Parvifolius L. and Pemisetum flaccidum Griseb by weight, pulverize and be fine powder, be prepared into unguentum by conventional method.For example, can directly be mixed into paste, also can be brewed into paste, can also be brewed into paste etc. by Adeps sus domestica with Oleum Sesami with vaseline.
The pharmaceutical composition that is used to treat nasal cavity inflammation property disease of the present invention shows through clinical trial, and it has following effect: expelling wind and cold, sensible gas are smooth, reducing swelling and alleviating pain, reparation nasal membrane pathological tissues.Indication: chronic rhinitis; Sinusitis; Allergic rhinitis; Vasomotor rhinitis; Various rhinitis symptoms such as atrophic rhinitis also have better curative effect to other diseases of nasal cavity, and non-evident effect.
The method for using that is used to treat the pharmaceutical composition of nasal cavity inflammation property disease of the present invention: mainly the form with ointment is coated with use outward.Absorbent cotton is twisted into streak cotton rod, with cotton rod revolve be stained with ointment after, fill in the nostril and get final product.Once a day, each two hours, bedtime medication was best.30 days is a course of treatment.Can fully recover a general course of treatment.
The specific embodiment
Below will specify the present invention through specific embodiment; In these embodiment; The source of the raw material that adopts is: Flos Magnoliae, the Radix Angelicae Dahuricae, Rubus Parvifolius L., Pemisetum flaccidum Griseb all can be bought through approach such as medical material markets, and the operative norm of product is " Chinese Pharmacopoeia 2010 version one one ".
Embodiment 1:
The pharmaceutical composition that is used to treat nasal cavity inflammation property disease of the present invention is pure compound Chinese medicinal preparation, is processed by effective raw material that following weight is formed:
10 parts of Flos Magnoliaes, 12 parts of the Radixs Angelicae Dahuricae, 20 parts of Rubus Parvifolius L.s, 10 parts of Pemisetum flaccidum Grisebs.
The dosage form of present embodiment is a unguentum, and method for preparing is following:
Above-mentioned various raw materials rollings are broken, stir synthetic paste with vaseline and get final product.
Embodiment 2:
The pharmaceutical composition that is used to treat nasal cavity inflammation property disease of the present invention is pure compound Chinese medicinal preparation, is processed by effective raw material that following weight is formed:
8 parts of Flos Magnoliaes, 13 parts of the Radixs Angelicae Dahuricae, 19 parts of Rubus Parvifolius L.s, 10 parts of Pemisetum flaccidum Grisebs.
The dosage form of present embodiment is a unguentum, and method for preparing is following:
Above-mentioned various raw materials rollings are broken, be brewed into paste with Oleum Sesami and get final product.
Embodiment 3:
The pharmaceutical composition that is used to treat nasal cavity inflammation property disease of the present invention is pure compound Chinese medicinal preparation, is processed by effective raw material that following weight is formed:
9 parts of Flos Magnoliaes, 14 parts of the Radixs Angelicae Dahuricae, 21 parts of Rubus Parvifolius L.s, 7 parts of Pemisetum flaccidum Grisebs.
The dosage form of present embodiment is a unguentum, and method for preparing is following:
Above-mentioned raw materials is rolled over broken, mix into paste with vaseline and get final product.
Embodiment 4:
The pharmaceutical composition that is used to treat nasal cavity inflammation property disease of the present invention is pure compound Chinese medicinal preparation, is processed by effective raw material that following weight is formed:
11 parts of Flos Magnoliaes, 16 parts of the Radixs Angelicae Dahuricae, 15 parts of Rubus Parvifolius L.s, 14 parts of Pemisetum flaccidum Grisebs.
The dosage form of present embodiment is a unguentum, and method for preparing is following:
Above-mentioned raw materials is rolled over broken, mix into paste with vaseline and get final product.
Embodiment 5:
The pharmaceutical composition that is used to treat nasal cavity inflammation property disease of the present invention is pure compound Chinese medicinal preparation, is processed by effective raw material that following weight is formed:
6 parts of Flos Magnoliaes, 9 parts of the Radixs Angelicae Dahuricae, 26 parts of Rubus Parvifolius L.s, 10 parts of Pemisetum flaccidum Grisebs.
The dosage form of present embodiment is a unguentum, and method for preparing is following:
Above-mentioned raw materials is rolled over broken, mix into paste with vaseline and get final product.
Embodiment 6:
The pharmaceutical composition that is used to treat nasal cavity inflammation property disease of the present invention is pure compound Chinese medicinal preparation, is processed by effective raw material that following weight is formed:
5 parts of Flos Magnoliaes, 8 parts of the Radixs Angelicae Dahuricae, 10 parts of Rubus Parvifolius L.s, 5 parts of Pemisetum flaccidum Grisebs.
The dosage form of present embodiment is a unguentum, and method for preparing is following:
Above-mentioned raw materials is rolled over broken, mix into paste with vaseline and get final product.
Embodiment 7:
The pharmaceutical composition that is used to treat nasal cavity inflammation property disease of the present invention is pure compound Chinese medicinal preparation, is processed by effective raw material that following weight is formed:
15 parts of Flos Magnoliaes, 20 parts of the Radixs Angelicae Dahuricae, 30 parts of Rubus Parvifolius L.s, 15 parts of Pemisetum flaccidum Grisebs.
The dosage form of present embodiment is a unguentum, and method for preparing is following:
Above-mentioned raw materials is rolled over broken, mix into paste with vaseline and get final product.
Embodiment 8: the clinical trial of pharmaceutical composition of the present invention
Pharmaceutical composition of the present invention is used through out-patient's 580 examples, is divided into treatment group and matched group at random.Wherein, 290 examples are organized in treatment, adopt the unguentum of preparation of pharmaceutical compositions of the present invention, minimum 14 years old of age, maximum 58 years old; The state of an illness is the shortest 80 days, and is the longest more than 20 years, and the severity extent patients with mild accounts for 40%, and moderate patient accounts for 50%.Matched group 290 examples adopt existing treatment rhinitis medicine on the market (for example production firm is the commodity " BIYANKANG " by name of Foshan Dezhong Pharmaceutical Co., Ltd.), minimum 15 years old of age, maximum 56 years old; The state of an illness is the shortest 67 days, and is the longest 17 years; Severity extent patients with mild 20%, moderate patient 66%.
Clinical test results is seen table 1; The result shows: the cure rate of treatment group reaches 90%, and (the recovery from illness performance: nasal airflow is good; Headache disappears, and secretions reduces, and concha nasalis is unloose); Effective percentage 98% (effectively performance: the big situation of nasal airflow situation and concha nasalis all before has improvement, but abnormal fully yet).The cure rate of treatment group and effective percentage all are higher than matched group, and the inefficiency of treatment group significantly is lower than matched group.
Table 1: clinical test results
| Group | Number | Cure rate (%) | Effective percentage (%) | Inefficiency (%) |
| The treatment group | 290 | 90 | 98 | 2 |
| Matched group | 290 | 70 | 75 | 25 |
Several routine clinical practice instances are following:
Instance 1: Zhu, the woman, 37 years old, the big drop people of Nanhai District suffered from surplus the chronic rhinitis 16 year, persistence nasal obstruction, rhinorrhea.With one course of treatment of BIYANLING of the present invention, transference cure is ventilated, and the concha nasalis enlargement disappears, and does not have recurrence in 3 years.
Instance 2: the Wang, the man, 43 years old, people from Foshan suffered from chronic sinusitis 15 years.Headache, nasal obstruction has dense tears, obstinate.Through using two courses of treatment of rhinitis ointment of the present invention, transference cure, ventilation is good, and the concha nasalis enlargement disappears, and the nasal membrane reparation is well.
Instance 3: Ma, the man, 35 years old, three water people suffered from allergic rhinitis 10 years, early morning sneeze, stream clear water appearance nasal mucus, nasal membrane pale asphyxia, hyposmia.Through fully recovering after one course of treatment, do not see recurrence in 5 years with BIYANLING of the present invention.
Instance 4: Chen, the woman, 53 years old, Guangzhou Fang Cun people suffered from chronic rhinitis 7 years.Nasal obstruction, intermittent nasal obstruction, the concha nasalis enlargement.Through using course of treatment of rhinitis ointment of the present invention, nasal airflow is good, recurrence in 4 years.
Instance 5: Liu, the man, 49 years old, the high person of good sense in Foshan City suffered from chronic sinusitis 26 years, headache, nasal obstruction is serious, and nasal cavity has dense crust, and poor effect is handled in puncture once.After use BIYANLING posterula two courses of treatment ventilation of the present invention good, headache alleviates.Continue medication, after another course of treatment, symptom disappears entirely, not recurrence in 2 years.
In sum, the pharmaceutical composition that is used to treat nasal cavity inflammation property disease of the present invention, prescription is simple; Pure Chinese medicine ingredients, reasonable recipe has no side effect; Easy to use, can fully recover good effect a general course of treatment; Efficacy stability, relapse rate is low, can effect a radical cure multiple nose diseasess such as rhinitis, sinusitis.
Claims (6)
1. a pharmaceutical composition that is used to treat nasal cavity inflammation property disease is characterized in that, each raw materials in part by weight is: Flos Magnoliae 5-15 part, Radix Angelicae Dahuricae 8-20 part, Rubus Parvifolius L. 10-30 part, Pemisetum flaccidum Griseb 5-15 part.
2. the pharmaceutical composition that is used to treat nasal cavity inflammation property disease according to claim 1 is characterized in that, each raw materials in part by weight is: 10 parts of Flos Magnoliaes, 12 parts of the Radixs Angelicae Dahuricae, 20 parts of Rubus Parvifolius L.s, 10 parts of Pemisetum flaccidum Grisebs.
3. pharmaceutical composition according to claim 1 is characterized in that: described nasal cavity inflammation property disease comprises: chronic rhinitis, sinusitis, allergic rhinitis, vasomotor rhinitis, atrophic rhinitis.
4. pharmaceutical composition according to claim 1 is characterized in that: described pharmaceutical composition is processed the outer unguentum that is coated with use.
5. the preparation of drug combination method that is used to treat nasal cavity inflammation property disease as claimed in claim 1; It is characterized in that; May further comprise the steps: take by weighing Flos Magnoliae, the Radix Angelicae Dahuricae, Rubus Parvifolius L. and Pemisetum flaccidum Griseb by weight, pulverize and be fine powder, be prepared into medicament by conventional method.
6. method for preparing according to claim 5 is characterized in that: described medicament is for being coated with the unguentum of use outward.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210180172.2A CN102697894B (en) | 2012-06-04 | 2012-06-04 | Medicinal composition for treating nasal cavity inflammatory disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210180172.2A CN102697894B (en) | 2012-06-04 | 2012-06-04 | Medicinal composition for treating nasal cavity inflammatory disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102697894A true CN102697894A (en) | 2012-10-03 |
| CN102697894B CN102697894B (en) | 2014-04-30 |
Family
ID=46891141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210180172.2A Expired - Fee Related CN102697894B (en) | 2012-06-04 | 2012-06-04 | Medicinal composition for treating nasal cavity inflammatory disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102697894B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306450A (en) * | 2021-12-21 | 2022-04-12 | 韩秉谦 | A topical Chinese medicinal composition for treating nasal diseases, and its preparation method |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1704094A (en) * | 2004-05-27 | 2005-12-07 | 胡章英 | Chinese medicine for curing rhinitis |
| WO2006007758A1 (en) * | 2004-07-16 | 2006-01-26 | Zhiquan Zhao | Traditional chinese medicine composition for treating acute and chronic nasosinusitis and preparation thereof |
| CN1965900A (en) * | 2006-11-09 | 2007-05-23 | 杨承祖 | Externally applied Chinese medicinal composition for treating nasal sinuitis |
| CN101623328A (en) * | 2008-07-08 | 2010-01-13 | 孙敬兰 | Chinese medicinal preparation and its preparation method |
| CN101703574A (en) * | 2009-12-03 | 2010-05-12 | 秦开锋 | Medicament for treating sinusitis |
| KR20110036317A (en) * | 2009-10-01 | 2011-04-07 | 재단법인 제주테크노파크 | Anti-inflammatory composition |
| CN102178736A (en) * | 2011-04-29 | 2011-09-14 | 冯宇伟 | Medicament for treating nasosinusitis |
| KR20110138082A (en) * | 2010-06-18 | 2011-12-26 | 한국 한의학 연구원 | Composition for immunopotentiating comprising the extract of herbal formula, ojeok-san |
-
2012
- 2012-06-04 CN CN201210180172.2A patent/CN102697894B/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1704094A (en) * | 2004-05-27 | 2005-12-07 | 胡章英 | Chinese medicine for curing rhinitis |
| WO2006007758A1 (en) * | 2004-07-16 | 2006-01-26 | Zhiquan Zhao | Traditional chinese medicine composition for treating acute and chronic nasosinusitis and preparation thereof |
| CN1965900A (en) * | 2006-11-09 | 2007-05-23 | 杨承祖 | Externally applied Chinese medicinal composition for treating nasal sinuitis |
| CN101623328A (en) * | 2008-07-08 | 2010-01-13 | 孙敬兰 | Chinese medicinal preparation and its preparation method |
| KR20110036317A (en) * | 2009-10-01 | 2011-04-07 | 재단법인 제주테크노파크 | Anti-inflammatory composition |
| CN101703574A (en) * | 2009-12-03 | 2010-05-12 | 秦开锋 | Medicament for treating sinusitis |
| KR20110138082A (en) * | 2010-06-18 | 2011-12-26 | 한국 한의학 연구원 | Composition for immunopotentiating comprising the extract of herbal formula, ojeok-san |
| CN102178736A (en) * | 2011-04-29 | 2011-09-14 | 冯宇伟 | Medicament for treating nasosinusitis |
Non-Patent Citations (1)
| Title |
|---|
| 张志华: "《蔬菜中的灵丹妙药》", 31 March 2009, article "大白菜的灵丹妙药方", pages: 053 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306450A (en) * | 2021-12-21 | 2022-04-12 | 韩秉谦 | A topical Chinese medicinal composition for treating nasal diseases, and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102697894B (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103405596B (en) | A kind of Chinese medicine for the treatment of sinusitis | |
| CN103463416A (en) | Traditional Chinese medicine preparation for treating rhinitis and pharyngitis | |
| CN104352587A (en) | Ointment for treating rhinitis | |
| CN101979022A (en) | Chinese medicinal mixture for treating chronic rhinitis | |
| CN103948680A (en) | Suppository used for treating lung cold-type rhinitis, and preparation method thereof | |
| CN101474381B (en) | Medicament for treating acute and chronic rhinitis as well as preparation method thereof and nasal cavity medicine delivery device | |
| CN102697894B (en) | Medicinal composition for treating nasal cavity inflammatory disease and preparation method thereof | |
| CN104399055A (en) | Traditional Chinese medicine composition for treating scapulohumeral periarthritis | |
| CN104587033A (en) | Nano-silver rhinitis cream | |
| CN103110774B (en) | Chinese herbal preparation for treating epistaxis and preparation method thereof | |
| CN104189605B (en) | Traditional Chinese preparation for treating acute nasopharyngitis and preparation method thereof | |
| CN103656090B (en) | A kind of enema and application thereof for the treatment of ulcerative colitis | |
| CN105055934A (en) | Medicine for treating chronic sinusitis and method for preparing medicine | |
| CN102350019B (en) | Rhinitis ointment nasal cavity feeder | |
| CN104547128A (en) | Medicine for treating rhinitis | |
| CN110721303A (en) | Traditional Chinese medicine composition for treating allergic rhinitis and application thereof | |
| CN104857414A (en) | Medicine composite for treating chronic simple rhinitis | |
| CN104740245A (en) | Traditional Chinese medicine for treating nasosinusitis | |
| CN103285169A (en) | Traditional Chinese medicine pill for treatment of chronic rhinitis | |
| CN104587035A (en) | Medicine composition for treating oral ulcer and preparation method for medicine composition | |
| CN104189083A (en) | Chinese herbal preparation for treating acute maxillary sinusitis | |
| CN104587034A (en) | New application of a medicinal composition in treating oral ulcer | |
| CN104587122A (en) | Traditional Chinese medicine composition for treating chronic gastritis | |
| CN104107409A (en) | Traditional Chinese medicine composition for treating rhinitis | |
| CN110755531A (en) | Traditional Chinese medicine composition for treating rhinitis and externally applied smearing type gel thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140430 Termination date: 20160604 |